Cutis
-
This article reviews various studies supporting the use of a fixed-combination monotherapy hydrating gel containing clindamycin 1% and benzoyl peroxide 5% (C/BPO), which is the only available formulation with a hydrating gel vehicle containing a humectant and an occlusive. The C/BPO hydrating gel provides a flexible and complementary efficacy and/or tolerability profile when used alone or with topical retinoids, which results in rapid response in inflammatory and noninflammatory acne. It also mitigates the irritation associated with disease flare or topical retinoid use, and reduces the postinflammatory hyperpigmentation (PIH) seen in women and in patients with skin of color with acne. These benefits are important because they have the potential to improve patient adherence to therapy and clinical outcomes.